Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Activating mutations in ALK provide a therapeutic target in neuroblastoma

Class:IdLiteratureReference:9700412
_displayNameActivating mutations in ALK provide a therapeutic target in neuroblastoma
_timestamp2020-09-16 05:15:06
author[Person:9700329] George, Rani E
[Person:6800488] Sanda, Takaomi
[Person:1614698] Hanna, M
[Person:9691833] Fröhling, Stefan
[Person:9700365] Luther, William
[Person:9671449] Zhang, Jianming
[Person:8956576] Ahn, Yebin
[Person:9700336] Zhou, Wenjun
[Person:9700384] London, Wendy B
[Person:9700388] McGrady, Patrick
[Person:2871818] Xue, Liquan
[Person:9700361] Zozulya, Sergey
[Person:9700345] Gregor, Vlad E
[Person:9700305] Webb, Thomas R
[Person:1225969] Gray, Nathanael S
[Person:4687067] Gilliland, D Gary
[Person:9700338] Diller, Lisa
[Person:1169426] Greulich, Heidi
[Person:2871826] Morris, Stephan W
[Person:9646562] Meyerson, Matthew
[Person:6800491] Look, A Thomas
created[InstanceEdit:9700359] Rothfels, Karen, 2020-09-16
journalNature
pages975-8
pubMedIdentifier18923525
titleActivating mutations in ALK provide a therapeutic target in neuroblastoma
volume455
year2008
(literatureReference)[Summation:9723305] Oncogenic point mutations in ALK promote ligand-independent ...
[EntityWithAccessionedSequence:9699801] ALK F1174L [plasma membrane] [Homo sapiens]
[EntityWithAccessionedSequence:9699831] ALK A1234T [plasma membrane] [Homo sapiens]
[EntityWithAccessionedSequence:9699853] ALK R1275Q [plasma membrane] [Homo sapiens]
[DefinedSet:9700568] NVP-TAE684-resistant ALK mutants [plasma membrane] [Homo sapiens]
[CandidateSet:9711929] PI3K-binding ALK mutants [cytosol] [Homo sapiens]
[CandidateSet:9711944] STAT3-activating ALK mutants [cytosol] [Homo sapiens]
[CandidateSet:9713538] SHC-binding ALK mutant dimers [cytosol] [Homo sapiens]
[FailedReaction:9700114] NVP-TAE684-resistant ALK mutants don't bind NVP-TAE684 [Homo sapiens]
[Reaction:9700131] ALK mutants bind type I TKIs [Homo sapiens]
List all 16 refering instances
[Change default viewing format]
No pathways have been reviewed or authored by Activating mutations in ALK provide a therapeutic target in neuroblastoma (9700412)